Publications

Publication Search Directions

The search fields below can be used to filter articles by Title, Author, Keyword, or Publication Name.

To see all available articles, ensure all search fields are cleared and click "Apply"

Title

Keywords

Author Last Name

Publication

Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree®): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder

External Link

http://doi.org/10.1002/brb3.2910

Authors

Faraone SV, Gomeni R, Hull JT et al

Journal

Brain Behav 2023;Feb 27;e2910

Year Published

2023

Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment

External Link

https://journals.sagepub.com/doi/10.1177/10870547231158572

Authors

Kosheleff AR, Mason O, Jain R et al

Year Published

2023

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

External Link

https://link.springer.com/article/10.1007/s40263-022-00938-w

Authors

Nasser A, Hull JT, Chaturvedi SA et al

Journal

CNS Drugs 2022;36:897-915

Year Published

2022

Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial

External Link

https://doi.org/10.1016/j.psychres.2022.114922

Authors

Faraone SV, Gomeni R, Hull JT et al

Journal

Psychiatry Res 2022;318:114922

Year Published

2022

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects

External Link

https://link.springer.com/article/10.1007/s13318-021-00729-6

Authors

Wang Z, Kosheleff AR, Adeojo LW et al

Journal

Eur J Drug Metab Pharmacokinet 2022;47:69

Year Published

2022

The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder

External Link

https://doi.org/10.1111/bcp.15412

Authors

Nasser A, Gomeni R, Wang Z et al

Journal

Br J Clin Pharmacol 2022;88:4828

Year Published

2022

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.

External Link

https://doi.org/10.1016/j.clinthera.2021.01.027

Authors

Nasser A, Liranso T, Adewole T et al

Journal

Clinical Therapeutics

Year Published

2021

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults

External Link

https://doi.org/10.1002/cpdd.948

Authors

Wang Z, Kosheleff AR, Adeojo LW et al

Journal

Clinical Pharmacology in Drug Development 2021, 00(0) 1–1

Year Published

2021

Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder

External Link

https://doi.org/10.1002/jcph.1940

Authors

Nasser A, Gomeni R, Wang Z, et al

Journal

J Clin Pharmacol 2021;61:1626-1637

Volume

61(12)

Year Published

2021

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

External Link

https://link.springer.com/article/10.1007/s40263-021-00825-w

Authors

Findling RL, Candler SA, Nasser AF et al

Journal

CNS Drugs 2021;35:643

Year Published

2021

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder

External Link

https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14330

Authors

Nasser A, Kosheleff AR, Hull JT et al

Journal

Int J Clin Pract 2021;75:e14330

Year Published

2021

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

External Link

https://journals.lww.com/psychopharmacology/Fulltext/2021/07000/A_Phase_3,_Plac…

Authors

Nasser A, Liranso T, Adewole T et al

Journal

J Clin Psychopharmacol 2021;41:370

Year Published

2021

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials

External Link

https://doi.org/10.2147/NDT.S312011

Authors

Nasser A, Hull JT, Liranso T et al

Journal

Neuropsychiatr Dis Treat 2021;17:1751

Year Published

2021

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

External Link

https://link.springer.com/article/10.1007/s40272-021-00470-2

Authors

Faraone SV, Gomeni R, Hull JT et al

Journal

Paediatr Drugs 2021;23:583

Year Published

2021

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder

External Link

https://link.springer.com/article/10.1007/s00787-021-01877-5

Authors

Faraone SV, Gomeni R, Hull JT et al

Journal

Eur Child Adolesc Psychiatry 2021;https://doi.org/10.1007/s00787-021-01877-5

Year Published

2021

Early response to SPN-812 (viloxazine extended-release) Can Predict Efficacy Outcome in Pediatric Subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

External Link

https://doi.org/10.1016/j.psychres.2020.113664

Authors

S. Faraone, Gomeni R, Hull JT et al

Journal

Psychiatry Research January 2021; 296:113664

Year Published

2021

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD

External Link

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146561/

Authors

Nasser A, Liranso T, Adewole T et al

Journal

Psychopharmacol Bull 2021;51:43

Year Published

2021

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Vilox

External Link

https://doi.org/10.1089/cap.2020.0148

Authors

Nasser A, Kosheleff AR, Hull JT et al

Journal

Journal Of Child And Adolescent Psychopharmacology

Year Published

2021

A Pooled Analysis of Four Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies Assessing Efficacy of SPN-812 (Viloxazine Extended Release) in Children and Adolescents With ADHD (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Nasser A, Hull, Chowdhry F et al

Journal

American Professional Society of ADHD and Related Disorders 2020 Annual Meeting

Year Published

2020

A Phase III, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Once-Daily SPN-812 (Viloxazine Extended-Release) in the Treatment of Attention-Deficit/Hyperactivity Disorder in School-age Children

External Link

https://doi.org/10.1016/j.clinthera.2020.05.021

Authors

Nasser A, Liranso T, Adewole T et al

Journal

Clinical Therapeutics 2020;42:1452-1466

Year Published

2020

New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties

External Link

https://doi.org/10.2147/JEP.S256586

Authors

Yu C, Garcia-Olivares J, Candler S et al

Journal

J Exp Pharmacol 2020;12:285-300

Year Published

2020

Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults

External Link

https://doi.org/10.4088/JCP.20m13395

Authors

Nasser A, Faison SL, Liranso T et al

Journal

Journal of Clinical Psychiatry;81:20m13395

Year Published

2020

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults

External Link

https://doi.org/10.1007/s40261-020-00992-6

Authors

Faison SL, Fry N, Adewole T et al

Journal

Clinical Drug Investigation 2020

Year Published

2020

Metabolism and in vitro drug-drug interaction assessment of viloxazine

External Link

https://www.tandfonline.com/doi/full/10.1080/00498254.2020.1767319

Authors

Yu C

Journal

Xenobiotica 2020;50:1285

Year Published

2020

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

External Link

https://doi.org/10.1177/1087054719836159

Authors

Johnson JK, Liranso T, Saylor K et al

Journal

J Atten Disord 2019;24:348

Year Published

2019

Structural Elucidation of the Major Human Metabolites of Viloxazine

External Link

https://supnpublications.supernus.com/request-a-poster

Year Published

2019

Efficacy of viloxazine ER in treating defiant/aggressive and risky decision-making behaviors in children and adolescents with ADHD (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Faraone SV, Gomeni R, Earnest J, Rubin J

Assessment of Pediatric Weight and Height Trajectories During Long-term Viloxazine ER (Qelbree®) Treatment: Interim Results from an Open-label Extension Trial in ADHD (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Earnest J, Hull JT, Koch J et al

Qelbree® (Viloxazine ER) Efficacy in Adults with ADHD Inattentive or Combined Presentations (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Cutler A, Childress A, Formella A et al

Efficacy of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Adults with Attention-Deficit/Hyperactivity Disorder: Results From an Open-Label Extension (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Nasser A, Hull JT, Earnest J et al

Characterization of Viloxazine’s Serotonergic Effects at Doses Relevant for ADHD Treatment (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Garcia-Olivares J, Yegla B, Earnest J et al

A Double-Blind, Placebo-Controlled, Dose-Ranging Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD (Poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Assessment of Serotonergic Effects of Viloxazine in Cynomolgus Monkeys Using PET Imaging with the [11C]CIMBI-36 Serotonin Receptor (5-HT2A/2C) Agonist Radioligand (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Garcia-Olivares J, Yegla B, Earnest J et al

Viloxazine Induces Dose-Dependent Increases in Interstitial Levels of Norepinephrine, Dopamine, and Serotonin in Rat Medial Prefrontal Cortex (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Yu C, Garcia-Olivares J, Yegla B et al

The Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function Assessed via the BRIEF-A in an Open-Label Extension Safety Trial of Adults with Attention-Deficit/Hyperactivity Disorder (poster)

External Link

https://supnpublications.supernus.com/request-a-poster

Authors

Hull JT, Chaturvedi SA, Rubin J, Nasser A

A legacy of innovation, a portfolio of promise ™

Publication Search Directions

A legacy of innovation, a portfolio of promise ^™